Histologic Risk Factor for Mortality and Development of Severe Liver Disease in Biopsy-proven Non-alcoholic Fatty Liver Disease

Jung Won Park; Jun Yong Park

doi:10.4166/kjg.2018.71.1.58

Journal List > Korean J Gastroenterol > v.71(1) > 1007768

Go to TopGo to Top Go to BottomGo to Bottom

See the article "".

TOOLS

Park and Park: Histologic Risk Factor for Mortality and Development of Severe Liver Disease in Biopsy-proven Non-alcoholic Fatty Liver Disease

Research Update

The Korean Journal of Gastroenterology 2018; 71(1): 58-60.

Published online: 25 January 2018

DOI: https://doi.org/10.4166/kjg.2018.71.1.58

Histologic Risk Factor for Mortality and Development of Severe Liver Disease in Biopsy-proven Non-alcoholic Fatty Liver Disease

Jung Won Park, Jun Yong Park

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Correspondence to: Jun Yong Park, Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Tel: +82-2-2228-1988, Fax: +82-2-393-6884, DRPJY@yuhs.ac

Korean Society of Gastroenterology

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article: Fibrosis Stage but Not NASH Predicts Mortality and Time to Development of Severe Liver Disease in Biopsy-proven NAFLD ([Related article:] J Hepatol 2017;67:1265-1273)

Notes

^{Financial support} None.

^{Conflict of interest} None.

References

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10:686–690.

2. Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology. 2016; 64:1969–1977.

3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55:2005–2023.

4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43:2 Suppl 1. S99–S112.

5. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017; 65:1557–1565.

6. Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: the importance of multistate models and competing risks analysis. Hepatology. 2015; 62:292–302.

7. Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67:1265–1273.

8. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41:1313–1321.

9. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015; 13:643–654. 654.e1–654.e9. quiz e39-e40.

10. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015; 62:1148–1155.

TOOLS

Similar articles